Studies highlight the clinical utility and real-world impact of the Nodify CDT® and Nodify XL2® tests in managing both benign and malignant pulmonary nodules.
.
03.10.2023 - Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi. These presentations will provide new insight . Seite 1